Patients with congenital hypogonadism show no abnormalities in childhood, and abnormalities usually appear during puberty or adulthood. The clinical examination of this disease is usually as follows.
1. Determination of serum testosterone (T): Most cases show a decrease. According to statistics, 79% of patients with the '47,XXY' type show a decrease, 33% of patients with the '46,XY/47,XXY' type show a decrease, and almost all patients with the '48,XXXY', '49,XXXYY', and '49,XXXXY' types show a decrease. Generally, the decrease is mild, and severe decreases are rare.
2. Determination of serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH): The level of serum FSH is increased in all cases, without overlap with normal people. The level of serum LH is increased in 75% of patients with the '47,XXY' type, 33% of patients with the '46,XY/47,XXY' type, and the majority of patients with the '48,XXXY', '49,XXXYY', and '49,XXXXY' types.
3. Determination of serum estradiol (E2): Most cases show an increase, and the increase is more obvious in patients with gynecomastia.
4. Determination of serum androgen-binding protein (ABP): Most cases show varying degrees of increase.
5. Human chorionic gonadotropin (HCG) test: The serum T response to HCG stimulation is reduced or normal, most of which are reduced to varying degrees.
6. Gonadotropin-releasing hormone (GnRH) test: The serum LH and FSH response to GnRH stimulation is often hyperreactive.
7. Sex chromosome examination: Oral mucosal scraping examination, the chromatin (Barr body) is positive for those with 2 or more X chromosomes.
8. Semen examination: Most patients with this disease have no sperm or few sperm, but a few patients with the
9. Chromosome examination: Generally, peripheral blood lymphocytes are used for karyotype analysis.
10. Testicular biopsy: The typical histological feature is hyaline degeneration of the seminiferous tubules, absence or significant reduction of spermatogenic cells, Leydig cell hyperplasia, which can present as pseudoadenomatous or nodular hyperplasia.